164 related articles for article (PubMed ID: 37686602)
1. Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells.
Mitobe Y; Suzuki S; Nakagawa-Saito Y; Togashi K; Sugai A; Sonoda Y; Kitanaka C; Okada M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686602
[TBL] [Abstract][Full Text] [Related]
2. The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo.
Mitobe Y; Suzuki S; Nakagawa-Saito Y; Togashi K; Sugai A; Sonoda Y; Kitanaka C; Okada M
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509605
[TBL] [Abstract][Full Text] [Related]
3. CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells.
Mitobe Y; Nakagawa-Saito Y; Togashi K; Suzuki S; Sugai A; Matsuda KI; Sonoda Y; Kitanaka C; Okada M
Anticancer Res; 2022 Oct; 42(10):4727-4733. PubMed ID: 36192008
[TBL] [Abstract][Full Text] [Related]
4. CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells.
Togashi K; Suzuki S; Mitobe Y; Nakagawa-Saito Y; Sugai A; Takenouchi S; Sugimoto M; Kitanaka C; Okada M
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201546
[TBL] [Abstract][Full Text] [Related]
5. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
6. Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule.
Grinkevich VV; Vema A; Fawkner K; Issaeva N; Andreotti V; Dickinson ER; Hedström E; Spinnler C; Inga A; Larsson LG; Karlén A; Wilhelm M; Barran PE; Okorokov AL; Selivanova G; Zawacka-Pankau JE
Front Mol Biosci; 2022; 9():823195. PubMed ID: 35720128
[TBL] [Abstract][Full Text] [Related]
7. Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type
Wang X; Yamamoto Y; Imanishi M; Zhang X; Sato M; Sugaya A; Hirose M; Endo S; Natori Y; Moriwaki T; Yamato K; Hyodo I
Oncol Lett; 2021 Jul; 22(1):558. PubMed ID: 34084225
[TBL] [Abstract][Full Text] [Related]
8. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
11. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
12. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
Espadinha M; Lopes EA; Marques V; Amaral JD; Dos Santos DJVA; Mori M; Daniele S; Piccarducci R; Zappelli E; Martini C; Rodrigues CMP; Santos MMM
Eur J Med Chem; 2022 Nov; 241():114637. PubMed ID: 35961068
[TBL] [Abstract][Full Text] [Related]
13. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
14. Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.
Lama R; Xu C; Galster SL; Querol-García J; Portwood S; Mavis CK; Ruiz FM; Martin D; Wu J; Giorgi MC; Bargonetti J; Wang ES; Hernandez-Ilizaliturri FJ; Koudelka GB; Chemler SR; Muñoz IG; Wang X
Front Oncol; 2022; 12():933446. PubMed ID: 35992795
[TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
[TBL] [Abstract][Full Text] [Related]
16. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
Verreault M; Schmitt C; Goldwirt L; Pelton K; Haidar S; Levasseur C; Guehennec J; Knoff D; Labussière M; Marie Y; Ligon AH; Mokhtari K; Hoang-Xuan K; Sanson M; Alexander BM; Wen PY; Delattre JY; Ligon KL; Idbaih A
Clin Cancer Res; 2016 Mar; 22(5):1185-96. PubMed ID: 26482041
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells.
Zhang S; Yan Z; Li Y; Gong Y; Lyu X; Lou J; Zhang D; Meng X; Zhao Y
J Med Chem; 2022 Apr; 65(8):6207-6230. PubMed ID: 35420431
[TBL] [Abstract][Full Text] [Related]
19. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.
Yurlova L; Derks M; Buchfellner A; Hickson I; Janssen M; Morrison D; Stansfield I; Brown CJ; Ghadessy FJ; Lane DP; Rothbauer U; Zolghadr K; Krausz E
J Biomol Screen; 2014 Apr; 19(4):516-25. PubMed ID: 24476585
[TBL] [Abstract][Full Text] [Related]
20. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
